IDNA ETF Analysis: Genomics Immunology | NYSE
Health | NYSE, USA | Market Cap: 273m USD | 12M Return: 77.4% | US46435U1925 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.30M
Warnings
No concerns identified
Tailwinds
Seasonality
The iShares Genomics Immunology and Healthcare ETF (IDNA) is a passively managed fund that invests at least 80% of its assets in securities that mirror its underlying index, with the flexibility to allocate up to 20% to derivatives such as futures, options, and swap contracts, as well as cash equivalents. The index targets developed and emerging market companies positioned to benefit from long-term advancements in genomics, immunology, and bioengineering-subsectors of biotechnology focused on gene-based research, immune system therapies, and engineered biological systems. The fund is structured as non-diversified, meaning it may hold a more concentrated portfolio compared to diversified ETFs, which can result in greater exposure to individual securities within the healthcare innovation theme.
- FDA approves breakthrough gene therapies and immunotherapies
- Biotech M&A wave lifts genomics sector valuations
- Drug pricing regulation pressures constituent margins
As of September 22, 2026, the stock is trading at USD 40.63 with a total of 223,134 shares traded. Over the past week, the price has changed by +4.88%, over one month by +1.37%, over three months by +32.35% and over the past year by +77.44%.
Current recommended Stop Loss: 39.50 (which is 2.8% or 1.3 ATR below the current price).
Genomics Immunology has no consensus analysts rating.